Most Recent Articles by Nicole Blazek, Senior Clinical Content Editor
Targeted milestones, areas poised for future discoveries, and areas of research that could benefit the most prioritized.
Currently FDA-approved for treating pseudo bulbar affect, the drug also benefits agitation.
The first randomized-controlled clinical trials are underway to assess if early access to amyloid imaging PET scan results can inform treatment decisions for mild cognitive impairment and dementia.
Investigators identified a possible disease-modifying effect of solanezumab as an early treatment for Alzheimer's disease, but the benefit in clinical practice remains unclear.
Among those with mild cognitive impairment, women's cognitive abilities deteriorated twice as quickly as men.
More Articles by Nicole Blazek, Senior Clinical Content Editor
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Correctional Psychiatry: Challenges and Rewards
- Color Vision Impairment in Schizophrenia May Be Due to Medication
- Sleep Disorders Linked to Nonaffective Psychosis in Young Adults
- Lithium May Treat Children With Bipolar Disorder, but Pediatric Studies Are Lacking
- Improvement in Guidelines for Monitoring Patients Receiving Lithium Essential
- The Opioid System: The Foundation for Social Risk and Reward
- Nomophobia: The Modern-Day Pathology
- Is Mandatory Reporting of Child Maltreatment in the Best Interests of the Child?
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Those Left Behind: Working With Suicide-Bereaved Families
- Associations Among Gender Nonconformity, Mental Distress, and Substance Use Among High School Students
- Digital Cognitive Therapy Eases Daytime Effects of Insomnia
- Predicting Poststroke Depression: Biomarkers and Beyond
- Sexual Harassment, Assault Tied to Women's Health Issues
- Daily Drinking Associated With Increased Mortality Risk